Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
KYNTRA BIO, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
kyntrabio.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kyntra Bio appointed Andrew E. Singer, an investment banking executive with biopharma expertise, as a Class III director and Audit Committee member effective October 1, 2026. This board expansion strengthens governance and strategic guidance for the company's oncology and rare disease focus.
Key Takeaways
Andrew E. Singer appointed as Class III director with term expiring in 2029, bringing investment banking and biopharma strategic expertise
Singer joins the Audit Committee, enhancing financial oversight and governance capabilities
2 more takeaways
Related Filings (1)
1 more filing from KYNTRA BIO, INC. in the last 90 days
Filing Overview
What This Means
KYNTRA BIO, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.